Prospective Analysis of Patients with Metastatic Breast Cancer receiving Eribulin Mesylate as Second or More Lines of Chemotherapy: An Indian Experience

Prospective Analysis of Patients with Metastatic Breast Cancer receiving Eribulin Mesylate as Second or More Lines of Chemotherapy: An Indian Experience

Background: Eribulin mesylate is a non-taxane microtubule inhibitor which can be used after anthracycline and taxane treatment in patients with metastatic breast cancer (MBC). The purpose of this study was to investigate the efficacy and safety of eribulin monotherapy in heavily pretreated patients...

Full description

Bibliographic Details
Main Authors: BJ Srinivasa, Bhanu Prakash Lalkota, Girish Badarke, Diganta Hazarika, Nasiruddin Mohammad, Sulav Sapkota, Mansi Khanderia, D Tousif, Raghavendra Rao, Amritanshu Ram, Shekar Patil, Radheshyam Naik
Format: Article
Language:English
Published: SAGE Publishing 2018-06-01
Series:Clinical Medicine Insights: Oncology
Online Access:https://doi.org/10.1177/1179554918782475

Internet

https://doi.org/10.1177/1179554918782475

Similar Items